Inflammatory diseases

Naïve, protein-naïve and non-naïve study subjects

Acute, short-infusion or repeated dosing designs.

General, tissue and cell-specific inflammatory evaluations.

Full clinical chemistry, clinical pathology and clinical toxicology support.

Tissue-specific safety biomarker levels by biosampling, biopsy or microdialysis.

Organ-specific or complete histology and pathology evaluation.

Naïve, protein-naïve and non-naïve study subjects

Acute, short-infusion or repeated dosing designs.

General, tissue and cell-specific inflammatory evaluations.

Full clinical chemistry, clinical pathology and clinical toxicology support.

Tissue-specific safety biomarker levels by biosampling, biopsy or microdialysis.

Organ-specific or complete histology and pathology evaluation.

Extensive inflammation models in cynomolgus and marmosets with functional and clinical assessments:

Dermal inflammation: DI

Irritable bowel diseases: IBD

Multiple sclerosis: MS

Respiratory/asthma/COPD: RAC

Sepsis/ endotoxemia: ET

Wound healing: WH

Dermal inflammation: DI

Irritable bowel diseases: IBD

Multiple sclerosis: MS

Respiratory / asthma / COPD: RAC

Sepsis/ endotoxemia: ET

Wound healing: WH

Comprehensive inflammation biomarkers assays:

Standard and expanded multiplexed cytokine assays

Immune markers (comprehensive CD markers panels by flow cytometry)

Acute phase proteins assays (CRP and SAA)

Cellular lipid markers assays

© 2019 Envol Biomedical. All Rights Reserved.